BRIEF-Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01

Reuters10-07

BRIEF-Relmada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01

Oct 7 (Reuters) - Relmada Therapeutics Inc RLMD.O:

RELMADA THERAPEUTICS APPOINTS DISTINGUISHED UROLOGIC ONCOLOGIST, MAX KATES, MD, TO THE CLINICAL ADVISORY BOARD TO SUPPORT DEVELOPMENT OF NDV-01

Source text: ID:nGNX8jQgpY

Further company coverage: RLMD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573595250?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573595250","market":"fut","top_or_hot":-1,"title":"BRIEF-Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01</title></head><body><p><span>Oct 7 (Reuters)</span><span> - </span>Relmada Therapeutics Inc <span>RLMD.O</span>:</p><ul><li><p>RELMADA THERAPEUTICS APPOINTS DISTINGUISHED UROLOGIC ONCOLOGIST, MAX KATES, MD, TO THE CLINICAL ADVISORY BOARD TO SUPPORT DEVELOPMENT OF NDV-01</p></li></ul><p>Source text: <span>ID:nGNX8jQgpY</span></p><p>Further company coverage: <span>RLMD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-07 19:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01</title></head><body><p><span>Oct 7 (Reuters)</span><span> - </span>Relmada Therapeutics Inc <span>RLMD.O</span>:</p><ul><li><p>RELMADA THERAPEUTICS APPOINTS DISTINGUISHED UROLOGIC ONCOLOGIST, MAX KATES, MD, TO THE CLINICAL ADVISORY BOARD TO SUPPORT DEVELOPMENT OF NDV-01</p></li></ul><p>Source text: <span>ID:nGNX8jQgpY</span></p><p>Further company coverage: <span>RLMD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA3NBVM4:1","article_id":"2573595250","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573595250","pubTimestamp":1759837944,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01Oct 7 (Reuters) - Relmada Therapeutics Inc RLMD.O:RELMADA THERAPEUTICS APPOINTS DISTIN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RLMD":"Relmada Therapeutics, Inc."},"translate_title":"简介-Relmada Therapeutics任命Max Kates医学博士为临床顾问委员会成员，以支持NDV-01的开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLMD":0.9},"content_text":"BRIEF-Relmada Therapeutics Appoints Max Kates, MD, To The Clinical Advisory Board To Support Development Of NDV-01Oct 7 (Reuters) - Relmada Therapeutics Inc RLMD.O:RELMADA THERAPEUTICS APPOINTS DISTINGUISHED UROLOGIC ONCOLOGIST, MAX KATES, MD, TO THE CLINICAL ADVISORY BOARD TO SUPPORT DEVELOPMENT OF NDV-01Source text: ID:nGNX8jQgpYFurther company coverage: RLMD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573595250","isCrawlerRequest":true}